Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow, and management explicitly draws the size contrast, treating it as the point. Let's review the transcript. Cathy Zoi and Olga discuss various partnerships, regulatory developments, and operational metrics. They mention the GM-Pilot partnership, the GSA BPA, NEVI program, etc. But do they describe a situation where the company is already serving a huge demand relative to its size, and management highlights that disproportion? Look for specific language: "we have already eclipsed the number of stalls we placed into operation in all of 2021" - that's about growth, not mismatch. "Throughput was 10.1 gigawatt hours, an increase of 66%" - that's growth. "Our customer count increased by 18% versus the first quarter" - growth. They talk about the federal government's fleet: "Supporting an entire electric federal fleet to require more than 100,000 new charging stations according to the government accountability office, EVgo is enthusiastically welcome to U. S. government's leadership and electrification and looks forward to helping agencies across the federal government meet their EV charging goals." That's about a future opportunity, not current participation. They have a BPA, but they say "Specific business projects will be announced by individual agencies as they formulate their own fleet electrification plan." So it's prospective. They mention the NEVI program: "we are expecting to see first solicitations from the states as early as the fourth quarter of 2022 or the first quarter of 2023." That's future. They mention the Inflation Reduction Act: "we are still working our way through the particulars of the bill" - future. They mention the GM-Pilot partnership: "we announced an EVgo extend product to deploy up to 2,000 charging stalls and up to 500 pilot and Flying J locations across the United States." That's a partnership, but is it already generating revenue? They say "EVgo will procure, construct, operate and maintain these charging cells, providing us with both an increase in near-term revenue and longer term contracted revenues." So it's a contract, but is it already in operation? They say "we have not disclosed the terms of this deal" and they talk about cash flow profile.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.